FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to preparations for continuous delivery of active substances. Disclosed is a composition for treating an eye pathology, comprising particles, wherein the particles contain an anticalin, a biodegradable polymer and one or more adjuvant and are capable of sustained continuous release of anticalin for at least two months; biodegradable polymer contains a poly(d,l-lactide-co-glycolide) copolymer with 75 mol % polylactic acid and 25 mol % polyglycolic acid and has an intrinsic viscosity in range of 0.50 dl/g to 0.70 dl/g; one or more adjuvants contains sulphobutylether-beta-cyclodextrin, trehalose, arginine or a combination thereof; wherein said excipients are present in amount of 5 to 15 % by weight based on the total weight of the composition, and the anticalin is present in amount of 5 to 50 % by weight. Also disclosed is use of said composition for treating eye pathologies and an aqueous preparation containing anticalin and one or more of said excipients.
EFFECT: group of inventions provides stabilization of highly concentrated solution of anticalin by using said excipients.
4 cl, 9 dwg, 4 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR LONG-TERM RELEASE OF PROTEIN | 2013 |
|
RU2676102C2 |
POLYMERIC PROTEIN MICROPARTICLES | 2012 |
|
RU2642664C2 |
POLYMER PROTEIN MICROPARTICLES | 2012 |
|
RU2768492C2 |
PROTEINS AND PROTEIN CONJUGATES WITH HIGH HYDROPHOBICITY | 2015 |
|
RU2712644C2 |
MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
VELDORETID, HAVING POOR SOLUBILITY IN PHYSIOLOGICAL CONDITIONS, FOR USE IN TREATING ACROMEGALY, ACROMEGALY WITH MALIGNANT GROWTH, EXPRESSING SST-R5 TUMORS, TYPE 2 DIABETES, HYPERGLYCEMIA AND TUMORS ASSOCIATED WITH HORMONES | 2017 |
|
RU2736590C2 |
OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
SUNITINIB-BASED COMPOSITIONS AND METHODS FOR USING THEM FOR TREATING EYE DISEASES | 2015 |
|
RU2729731C2 |
IL-6 ANTAGONISTS AND USES THEREOF | 2013 |
|
RU2670943C9 |
USE OF VEGF ANTAGONIST FOR TREATING RETINOPATHY OF PREMATURITY | 2014 |
|
RU2676303C2 |
Authors
Dates
2020-04-29—Published
2014-03-13—Filed